Literature DB >> 24172316

Bringing together the academic drug discovery community.

Barbara S Slusher1, P Jeffrey Conn, Stephen Frye, Marcie Glicksman, Michelle Arkin.   

Abstract

The newly formed Academic Drug Discovery Consortium (ADDC) aims to support the growing numbers of university centres engaged in drug discovery that have emerged in response to recent changes in the drug discovery ecosystem.

Entities:  

Mesh：

Year:  2013        PMID： 24172316      PMCID： PMC4076044          DOI： 10.1038/nrd4155

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  4 in total

1.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

3.  Trial watch: Phase II failures: 2008-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

4.  Trial watch: phase III and submission failures: 2007-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694
  4 in total
  13 in total

1.  Challenges with risk mitigation in academic drug discovery: finding the best solution.

Authors:  Anuradha Roy
Journal:  Expert Opin Drug Discov       Date:  2018-12-04       Impact factor: 6.098

2.  Academic-Industrial Collaboration: Toward the Consilience of Two Solitudes.

Authors:  Stephen Hanessian
Journal:  ACS Med Chem Lett       Date:  2015-12-22       Impact factor: 4.345

3.  Drug discoverers chart path to tackling data irreproducibility.

Authors:  Elie Dolgin
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

4.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

5.  Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.

Authors:  Maaike Everts; Mark J Suto; George R Painter; Richard J Whitley
Journal:  Future Virol       Date:  2016-02-29       Impact factor: 1.831

6.  A Curiously Linear Path to Academic Drug Discovery.

Authors:  Kathryn M Nelson
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

Review 7.  Valley of death: A proposal to build a "translational bridge" for the next generation.

Authors:  Nao J Gamo; Michelle R Birknow; Danielle Sullivan; Mari A Kondo; Yasue Horiuchi; Takeshi Sakurai; Barbara S Slusher; Akira Sawa
Journal:  Neurosci Res       Date:  2016-11-19       Impact factor: 3.304

8.  The Use of Informer Sets in Screening: Perspectives on an Efficient Strategy to Identify New Probes.

Authors:  Paul A Clemons; Joshua A Bittker; Florence F Wagner; Allison Hands; Vlado Dančík; Stuart L Schreiber; Amit Choudhary; Bridget K Wagner
Journal:  SLAS Discov       Date:  2021-06-16       Impact factor: 3.341

9.  The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.

Authors:  Johan Lundkvist; Magnus M Halldin; Johan Sandin; Gunnar Nordvall; Pontus Forsell; Samuel Svensson; Liselotte Jansson; Gunilla Johansson; Bengt Winblad; Jonas Ekstrand
Journal:  Front Pharmacol       Date:  2014-05-09       Impact factor: 5.810

10.  The 5th Annual One Mind Summit: Lessons Learned About "Science Informing Brain Health Policies and Practice".

Authors:  Ramona Hicks; Stephen Johnson; Amy C Porter; Douglas Zatzick
Journal:  J Neurotrauma       Date:  2017-05-17       Impact factor: 5.269
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.